Manufacturer
Aurobindo Pharma Limited (Unit III),
Contents
Efavirenz
Indication
HIV-1 infection.
Instruction
Should be taken on an empty stomach. Take preferably at bedtime.
Drug interaction
May reduce plasma concentrations of voriconazole, rifampicin, HIV non-nucleoside reverse transcriptase inhibitors (NNRTIs), HIV integrase inhibitors, Ca channel blockers, HMG-CoA reductase inhibitors (e.g. atorvastatin, pravastatin, simvastatin), immunosuppressants (e.g. ciclosporin, tacrolimus, sirolimus). May increase CNS effects with psychoactive drugs. May alter plasma warfarin concentrations resulting to increased or decreased anticoagulant effect.
Potentially Fatal: Increased risk of QTc interval prolongation and torsade de pointes with classes IA and III antiarrhythmics, neuroleptics, antidepressants, certain antibiotics (e.g. some macrolides, fluoroquinolones, imidazole and triazole antifungals), certain non-sedating antihistamines (e.g. terfenadine, astemizole), cisapride, flecainide, certain anti-malarial (e.g. atovaquone/proguanil) and methadone. Increased risk of serious reactions (e.g. prolonged sedation, respiratory depression) with midazolam, triazolam, pimozide, bepridil, ergot alkaloids (e.g. ergotamine, ergonovine). May significantly decrease plasma concentrations leading to loss of virologic response of elbasvir/grazoprevir.
Malaysia
